Degenerative Myopia

• EMA approval · 2026-08-21
  EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.

  EU authorizes Rimmyrah (ranibizumab) from Qilu Pharma Spain S.L. for indications including wet age-related macular degeneration, macular ede…

• EMA approval · 2026-06-15
  EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.

  The EMA authorises Rimmyrah (ranibizumab) by Qilu Pharma Spain S.L. for multiple ophthalmic indications including wet age-related macular de…

• EMA approval · 2026-02-26
  EMA Authorised: Yesafili (aflibercept) — Biosimilar Collaborations Ireland Limited

  Yesafili is an authorised aflibercept biosimilar by Biosimilar Collaborations Ireland Limited for various retinal diseases, expanding treatm…

• EMA approval · 2026-02-25
  EMA Authorised: Byooviz (ranibizumab) — Samsung Bioepis NL B.V.

  EMA authorised Byooviz (ranibizumab) from Samsung Bioepis NL B.V. for multiple retinal diseases, including wet age-related macular degenerat…

• EMA approval · 2020-09-16
  EMA Authorised: Visudyne (verteporfin) — CHEPLAPHARM Arzneimittel GmbH

  EMA confirms authorisation of Visudyne (verteporfin) by CHEPLAPHARM Arzneimittel GmbH for indications related to degenerative myopia and mac…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2014-06-04
  Clinical Trial Update: A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV [Phase 3]

  Phase 3 randomized, double-blind, multicenter, sham-controlled study assessing the safety and efficacy of Conbercept in patients with myopic…

• CLINICAL_TRIALS research · 2011-03-29
  Clinical Trial Update: Early Vitrectomy for Macular Tractional Maculopathy [NA]

  This clinical trial update discusses early vitrectomy for macular tractional maculopathy in patients with degenerative myopia. The status of…

• CLINICAL_TRIALS trial_result · 2009-02-03
  Clinical Trial Update: Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD) [Phase 1]

  Phase 1 trial evaluating bevacizumab (Avastin) infusion for choroidal neovascularization not associated with age-related macular degeneratio…